The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR congress coverage
Stay up to date with the latest developments in acute myeloid leukemia with our live social media coverage from the the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, February 12–16, Honolulu, US.
CONGRESS | #Tandem25 | PRESENTATION@NelliBejanyanMD, @MoffittNews, presents findings from a phase I trial evaluating ex-vivo expanded donor gamma delta T cell (GDT) immunotherapy to prevent post-HCT relapse of AML. GDT cell expansion was successful in all 12 treated patients,… pic.twitter.com/YBEp4ylFe9
— AML Hub (@AML_Hub) February 13, 2025
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 14, 2025
Uday Popat, @MDAndersonNews, presents results from a phase II trial evaluating myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa and venetoclax (Cladillac) conditioning regimen for allo-HSCT in 49 patients with very… pic.twitter.com/DCU5X6oeT3
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 15, 2025
Robert Zeiser, @UniFreiburg, discusses strategies for preventing AML relapse after transplant, such as targeting MDM2 to increase MHC-II expression and using anti-TIM-3 antibodies to enhance GVL effects.
Follow our live feed for more updates:… pic.twitter.com/LciOn4K2xC
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 15, 2025
Venessa Kennedy, @Stanford, shares insights on next generation allogeneic transplant strategies for AML. They highlight potential approaches, including CD117 targeting with briquilimab + NMA conditioning in high-risk AML/MDS; cellular… pic.twitter.com/PEZCOzuBbY
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 15, 2025
Yi-Bin Chen, @harvardmed, provides insights into the role of MRD testing in post-HCT maintenance for AML. He discusses various maintenance treatment options, including FLT3 inhibitors, HMAs, IDH1/2 inhibitors, and menin inhibitors, and their… pic.twitter.com/e1JqEJOIPt
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 15, 2025
Danielle Kirkey, @fredhutch, discusses a novel immunotherapeutic target —CLEC2A—which is highly enriched in high-risk KMT2Ar and monosomy 7 AML. Preclinical studies showed that CLEC2A CAR T cells exhibited target-restricted AML killing and… pic.twitter.com/tvTSrNpcvC
CONGRESS | #Tandem25 | PRESENTATION@DrMonzrAlMalki, @cityofhope, presents preliminary results from the phase I ALLOHA trial (NCT05473910) evaluating TSC-100 and TSC-101 TCR-T cells as maintenance treatment post-HCT to prevent relapse in patients with AML, ALL, or MDS undergoing… pic.twitter.com/YiN8CJOPrx
— AML Hub (@AML_Hub) February 16, 2025
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 16, 2025
John F. DiPersio @DiPersioLab, @WashUOncology, presents preliminary results from the phase I/II VBP101 trial (NCT04849910) of trem-cel, a CD33-deleted allograft, followed by GO maintenance in patients with CD33+ AML or MDS with high-risk of… pic.twitter.com/BotOezTnHV
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content